AZD0305
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AZD0305, covering 2026-01-27 to 2026-01-27. Get the full timeline:
Most recent: Clinical Trial Update: AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]